Explore the Usage of Simvastatin with Escitalopram to Manage Depression
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on December 19th, 2025
|
As Vietnam’s diet and lifestyle patterns have shifted, obesity rates have risen sharply. At the same time, improved diagnosis and changing social conditions have contributed to a growing prevalence of depression. These two conditions often occur together, compounding chronic health burdens and increasing mortality risk. With support from the German Ministry of Education and Research, researchers conducted a study to investigate whether simvastatin could help manage both depression and obesity.
The study enrolled 160 adults with an average age of 39 years who met DSM-5 criteria for major depressive disorder. Their mean baseline score on the Montgomery–Åsberg Depression Rating Scale (MADRS) was 25.5, indicating moderate depression. Participants also had a high average body mass index of 39.1, and 22 percent had LDL cholesterol levels above 100 mg/dL.
All participants received escitalopram for depression, starting at 10 mg daily and increasing to 20 mg after two weeks. They were then randomly assigned to receive either placebo or simvastatin at 40 mg daily. The rationale for testing simvastatin alongside antidepressants stems from its potential to reduce inflammation and stress-related hormones, both of which may worsen depressive symptoms.
After 12 weeks, the study found no significant difference in depression severity between the simvastatin group and the escitalopram-only group. However, simvastatin did lead to reductions in LDL cholesterol and C-reactive protein. Additionally, future research should explore longer treatment durations and evaluate the combination with different classes of antidepressants.
The study enrolled 160 adults with an average age of 39 years who met DSM-5 criteria for major depressive disorder. Their mean baseline score on the Montgomery–Åsberg Depression Rating Scale (MADRS) was 25.5, indicating moderate depression. Participants also had a high average body mass index of 39.1, and 22 percent had LDL cholesterol levels above 100 mg/dL.
All participants received escitalopram for depression, starting at 10 mg daily and increasing to 20 mg after two weeks. They were then randomly assigned to receive either placebo or simvastatin at 40 mg daily. The rationale for testing simvastatin alongside antidepressants stems from its potential to reduce inflammation and stress-related hormones, both of which may worsen depressive symptoms.
After 12 weeks, the study found no significant difference in depression severity between the simvastatin group and the escitalopram-only group. However, simvastatin did lead to reductions in LDL cholesterol and C-reactive protein. Additionally, future research should explore longer treatment durations and evaluate the combination with different classes of antidepressants.